The company focuses on developing transformative drugs for fatal and debilitating diseases with no approved therapies. They leverage technological advances and regulatory pathways to design drugs targeting validated molecular targets in areas of significant unmet medical needs. Their lead product candidate, AT-001, is a novel treatment for diabetic cardiomyopathy, a fatal fibrosis of the heart. Applied Therapeutics aims to create life-changing treatments for patients in need.